<qa>  What is the maximum tolerated dose of Xcellerated T Cells?This is a Phase III single arm dose escalation study of a novel T cell immunotherapy for chronic lymphocytic leukemia CLL. Patients will receive one dose of Xcellerated T Cellstm, an ex vivo activated and expanded autologous T cell product, in an attempt to enhance immune responses with anti-tumor activity. This study is being conducted to test the safety and determine the maximum tolerated dose MTD of Xcellerated T Cells in patients with CLL. In addition, lymphocyte counts, lymph node area, and quantitative immunoglobulins will be assessed for preliminary evidence of a therapeutic effect. In correlative studies, changes in the phenotype of T and B lymphocytes will be evaluated by flow cytometry. Changes in T cell repertoire and anti-tumor immune activity will also be assessed. It is expected that 12 to 18 patients will be treated. 